Postmenopausal osteoporosis is a condition affecting millions of women worldwide. It is characterised by decreased bone density in women of postmenopausal age which in turn increases the fragility of bones and making them susceptible to increased risk of sudden and unexpected bone fractures. The cause of postmenopausal osteoporosis is not clearly identified, however, the decrease in bone density is directly linked to deficiency of estrogen, a natural consequence of menopause in women. Since, menopause is an inevitable part of a women’s life, postmenopausal women are at high risk of being affected with osteoporosis. Other risk factors include family history, body weight and bone structure. In osteoporosis, bone mineral density (BMD) drops down to levels below normal range, which can be measured by a bone density scan. The treatment of postmenopausal osteoporosis includes medications to treat osteoporosis specifically such as selective estrogen receptor modulator (SERM), bisphosphonates, monoclonal antibodies, calcium, Vitamin D analogues and hormone replacement therapy (HRT). In addition to the existing classes of drugs, many new drugs are under development for the treatment of postmenopausal osteoporosis.
The main growth drivers for the pipeline of postmenopausal osteoporosis therapeutics include increasing ageing women population, innovations in the osteoporosis drug development market, increasing investment on healthcare infrastructure, rising awareness and consciousness among women about the risk of postmenopausal osteoporosis.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/post-menopausal-osteoporosis-therapeutics-pipeline-analysis/toc-sample
The key market players having a pipeline for postmenopausal osteoporosis include Eli Lilly and Company, Pfizer, Inc., F. Hoffman La Roche, Shire plc, Merck Sharp & Dohme Corp., GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Novartis AG, Amgen Inc., Eisai Co., Ltd., Sanofi S.A., Procter & Gamble Co., Radius Health, Inc., Tarsa Therapeutics, Inc., Zosano Pharma Inc., Ligand Pharmaceuticals, Alvogen Korea Co.Ltd, Nordic Bioscience A/S, CMX Research Inc., PhytoHealth Corporation, TransPharma Medical, Yuyu Pharma, Inc., Bayer AG, Deltanoid Pharmaceuticals, Hanlim Pharm. Co., Ltd., Takeda Pharmaceutical Company Ltd., Asahi Kasei Pharma Corporation, Ono Pharma USA Inc., Nastech Pharmaceutical Company, Inc., Azelon Pharmaceuticals, Bionovo, and Zelos Therapeutics.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)